BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response
- 1 November 2019
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 465, 45-58
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (U01 CA182898, R01 CA222170)
This publication has 54 references indexed in Scilit:
- Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from hereCancer, 2018
- Immunotherapy in triple-negative breast cancerMedical Oncology, 2017
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsScience Translational Medicine, 2016
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199Journal of Clinical Oncology, 2014
- PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2014
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialAnnals of Oncology, 2014
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98Journal of Clinical Oncology, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancerBreast Cancer Research, 2012